Table 1. Baseline characteristics of patients with ulcerative colitis.
| All patients | MH | No MH | P-value | |
|---|---|---|---|---|
| n (%) | 29 (100) | 13 (45) | 16 (55) | |
| Gender (male/female) | 19/10 | 7/6 | 12/4 | 0.3 |
| BMI, kg/m2, mean±s.d. | 25.6±4.1 | 26.4±4.6 | 25.0±3.6 | 0.5 |
| UC extension: E3 (pancolitis), n (%)a | 11 (44) | 4 (31) | 7 (44) | 0.4 |
| Mayo endoscopic sub-score before IFX, Mayo 3 (%) | 12 (41) | 4 (31) | 8 (50) | 0.5 |
| Acute severe colitis, n | 2 | 1 | 1 | 1.0 |
| Age at first IFX, y, median (IQR) | 43 (28–51) | 29 (24–53) | 45 (31–51) | 0.4 |
| Duration of disease at first IFX, y, median (IQR) | 3.0 (1.4–8.4) | 3.4 (1.9–8.0) | 2.3 (1.3–9.4) | 0.5 |
| CRP concentration, mg/l, median (IQR) | 3.7 (2.1–13.4) | 3.7 (1.5–14.2) | 3.5 (2.2–12.0) | 0.8 |
| Albumin, g/l, median (IQR) | 42.5 (39.7–45.4) | 42.1 (40.7–44.9) | 43.2 (38.4–45.9) | 0.9 |
| Current smokers, n | 4 | 3 | 1 | 0.3 |
| Immunomodulator use, n (%) | 12 (41) | 8 (62) | 4 (25) | 0.07 |
| Corticosteroid use, n (%) | 9 (31) | 3 (23) | 6 (38) | 0.5 |
BMI, body mass index; CRP, C-reactive protein; IFX, infliximab; IQR, interquartile range; MH, mucosal healing; UC, ulcerative colitis.
a
According to Montreal classification.